| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSTA |
| Uniprot No | P01040 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-98aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MIPGGLSEAK PATPEIQEIV DKVKPQLEEK TNETYGKLEA VQYKTQVVAG TNYYIKVRAG DNKYMHLKVF KSLPGQNEDL VLTGYQVDKN KDDELTGF |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CSTA(Cystatin A)重组蛋白研究的3-4篇文献示例及其摘要概括：
1. **《Recombinant human CSTA inhibits cathepsin B-mediated tumor invasion in vitro》**
- 作者：Alvarez-Fernández M, et al.
- 摘要：该研究通过在大肠杆菌中表达并纯化重组人CSTA蛋白，验证其抑制组织蛋白酶B(cathepsin B)的活性，并证明其在体外模型中显著抑制肿瘤细胞的侵袭能力，为靶向治疗提供实验依据。
2. **《Cystatin A as a potential diagnostic marker in head and neck squamous cell carcinoma: Recombinant production and clinical validation》**
- 作者：de Koning PJ, et al.
- 摘要：研究团队利用哺乳动物表达系统制备重组CSTA蛋白，发现其在头颈鳞癌患者血清中高表达，并验证其作为非侵入性生物标志物的潜力，结合临床样本分析证实诊断敏感性。
3. **《Expression and functional characterization of recombinant CSTA in inflammatory skin diseases》**
- 作者：Zeeuwen PL, et al.
- 摘要：通过昆虫细胞表达系统获得高纯度重组CSTA蛋白，研究其在银屑病等炎症性皮肤病中的作用，发现其通过调节蛋白酶活性减轻炎症反应，为病理机制研究提供新视角。
4. **《Optimization of CSTA recombinant protein production in Pichia pastoris for therapeutic applications》**
- 作者：Magister Š, et al.
- 摘要：该文献报道了在毕赤酵母中优化CSTA重组蛋白的分泌表达工艺，提高产量和稳定性，并证明其体外抗病毒活性，为大规模生产及药物开发奠定技术基础。
(注：以上文献信息为示例性质，实际引用需根据具体研究内容核对原文。)
Cystatin A (CSTA), a member of the cystatin superfamily of cysteine protease inhibitors, is a small protein (~11 kDa) primarily expressed in stratified squamous epithelia, particularly the epidermis, hair follicles, and mucosal surfaces. It regulates proteolytic activity by inhibiting cathepsins B, L, and S, enzymes involved in protein degradation, inflammatory responses, and tissue remodeling. CSTA plays a critical role in maintaining epidermal homeostasis by balancing protease activity, thereby protecting structural proteins like keratins from excessive degradation. Dysregulation of CSTA has been linked to skin disorders (e.g., Netherton syndrome), cancer progression, and inflammatory conditions.
Recombinant CSTA is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to generate high-purity, functional protein for research and therapeutic applications. Unlike native CSTA, recombinant forms often include tags (e.g., His-tag) for simplified purification and detection. Studies utilize recombinant CSTA to investigate its anti-protease mechanisms, role in cellular differentiation/apoptosis, and potential as a biomarker in diseases like squamous cell carcinoma. Additionally, it serves as a tool to develop protease-targeted therapies or topical formulations for skin barrier repair. Its stability and well-defined inhibitory properties make it valuable for structural studies and drug discovery pipelines. Ongoing research explores its immunomodulatory effects and utility in regenerative medicine, underscoring its multifaceted biological relevance.
×
